Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Robert Thomas Freeman, the Chief Financial Officer of Alignment Healthcare, Inc. (NASDAQ:ALHC), a $2.96 billion healthcare company whose stock has surged 214% over the past year, recently sold shares of the company’s stock, according to a regulatory filing made on March 13, 2025. The transactions, which occurred on March 12, involved the sale of 14,692 shares of common stock, totaling approximately $226,661. The shares were sold at a weighted-average price range between $15.4231 and $15.7379 per share, with the stock currently trading near its 52-week high of $16.25. According to InvestingPro, analysts maintain a bullish outlook on ALHC with a consensus Buy rating.
Following these transactions, Freeman holds 1,402,862 shares directly. Additionally, he has indirect ownership of 92,929 shares through FCO Holdings LLC, a limited liability company owned by FCO Holdings Trust One, of which Freeman is an indirect beneficiary.
The sales were conducted to cover tax withholding obligations related to the vesting of restricted stock units, and were not discretionary trades by Freeman.
In other recent news, Alignment Healthcare reported strong fourth-quarter 2024 earnings, beating analysts’ expectations with an EPS of -0.16 against a forecast of -0.18. The company also exceeded revenue projections, achieving $701.2 million compared to the anticipated $674.97 million. For the full year, Alignment Healthcare’s revenue reached $2.7 billion, marking a 48% year-over-year increase, while membership grew by 59%, driven by expansion beyond California. Looking ahead, the company provided 2025 revenue guidance between $3.72 billion and $3.78 billion, with an adjusted gross profit expected to range from $415 million to $445 million.
Analysts have shown confidence in Alignment Healthcare’s potential, with Piper Sandler raising the price target to $21.00 and maintaining an Overweight rating, citing the company’s scalable "flywheel" approach. Similarly, Raymond (NSE:RYMD) James increased the price target to $19.00 and reiterated a Strong Buy rating, following the company’s robust fourth-quarter performance. The firm’s strategies, particularly its high Star Ratings, are credited with improving patient engagement and reducing costs, which contribute to better member retention and quality bonus payments.
These developments suggest a promising outlook for Alignment Healthcare, with the company focusing on expanding its market presence and enhancing profitability. The company’s guidance for 2025 anticipates significant growth, with health plan membership expected to reach between 227,000 and 233,000 members. Analysts from Raymond James highlighted the company’s ability to grow at a rate of 20% or more annually while improving EBITDA profitability, leveraging its clinical model and operational scale.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.